sy-5609 Publications

TOLERABILITY AND PRELIMINARY ACTIVITY OF THE POTENT, SELECTIVE, ORAL CDK7 INHIBITOR SY-5609 IN COMBINATION WITH FULVESTRANT IN PATIENTS WITH ADVANCED HORMONE RECEPTOR-POSITIVE (HR+), HER2- BREAST CANCER (BC)

DEJAN JURIC, DEBRA L. RICHARDSON, BABAR BASHIR, MANISH SHARMA, KYRIAKOS P. PAPADOPOULOS, SARA MATHEWS, GRAEME HODGSON, SUSAN HENRY, SOFIA PAUL, TERENCE HALL, DAVID A. ROTH, MICHAEL KELLY, TANYA ABDUL MALAK, VIRGINIA KLIMEK

ASCO ANNUAL MEETING
ABSTRACT NUMBER: 3081
JUNE 2023

PHASE 1/1B STUDY OF SY-5609, A SELECTIVE AND POTENT CDK7 INHIBITOR, IN ADVANCED SOLID TUMORS AND IN 2L/3L PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) IN COMBINATION WITH GEMCITABINE +/- NAB-PACLITAXEL

BABAR BASHIR, MANISH SHARMA, DEJAN JURIC, KYRIAKOS P. PAPADOPOULOS, ERIKA P. HAMILTON, DEBRA L. RICHARDSON, GEOFFREY SHAPIRO, VAIBHAV SAHAI, NIHARIKA B. METTU, ZEV A. WAINBERG, OLATUNJI B. ALESE, TOMISLAV DRAGOVICH, GRAEME HODGSON, SUSAN HENRY, TERENCE HALL, SOFIA PAUL, DAVID A. ROTH, MICHAEL KELLY, TANYA ABDUL MALAK, VIRGINIA KLIMEK

ASCO ANNUAL MEETING
ABSTRACT NUMBER: 3080
JUNE 2023

SY-5609, A POTENT AND SELECTIVE CDK7 INHIBITOR, POTENTIATES BTK INHIBITOR ACTIVITY IN MANTLE CELL LYMPHOMA PRECLINICAL MODELS

LIV JOHANNESSEN, PRIYANKA SAWANT, ANTHONY D’IPPOLITO, NAN KE, ARIEL LEFKOVITH, MATTHEW EATON, WOJCIECH DWORAKOWSKI, MARIA ROSARIO, SUSAN HENRY, GRAEME HODGSON
63RD AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING
Abstract Number: 1205
2021

DISCOVERY OF SY-5609: A SELECTIVE, NONCOVALENT INHIBITOR OF CDK7

JASON J. MARINEAU, KRISTIN B. HAMMAN, SHANHU HU, SYDNEY ALNEMY, JANESSA MIHALICH, ANZHELIKA KABRO, KENNETH MATTHEW WHITMORE, DANA K. WINTER, STEPHANIE ROY, STEPHANIE CIBLAT, NAN KE, ANNELI SAVINAINEN, ASHRAF WILSILY, GORAN MALOJCIC, ROBERT ZAHLER, DARBY SCHMIDT, MICHAEL J. BRADLEY, NIGEL J. WATERS, CLAUDIO CHUAQUI
DOI: 10.1021/acs.jmedchem.1c01171
November 2021

TOLERABILITY AND PRELIMINARY CLINICAL ACTIVITY OF SY-5609, A HIGHLY POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS

Manish R. Sharma, Babar Bashir, Erika Hamilton, Dejan Juric, Kyriakos Papadopoulos, Debra Richardson, Geoffrey Shapiro, Graeme Hodgson, Nan Ke, Anthony D’Ippolito, Susan Henry, Li Zhu, Maria Rosario, Hina Jolin, David Roth, Virginia Klimek, Kate Madigan, Mike Kelly
ESMO Congress 2021
Oral Presentation
Abstract Number: 518MO
2021

SY-5609, A HIGHLY POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, EXHIBITS ROBUST ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF KRAS MUTANT CANCERS AS A SINGLE AGENT AND IN COMBINATION WITH CHEMOTHERAPY

Susan Henry, Liv Johannessen, Priyanka Sawant, Ariel Lefkovith, Nan Ke, Anthony D’Ippolito, Wojciech Dworakowski, Graeme Hodgson
ESMO Congress 2021
Abstract Number: 13P
2021

PRECLINICAL EVALUATION OF INTERMITTENT DOSING REGIMENS ON ANTITUMOR AND PD ACTIVITY OF SY-5609, A POTENT AND SELECTIVE ORAL CDK7 INHIBITOR, IN OVARIAN CANCER XENOGRAFTS

Liv Johannessen, Wojciech Dworakowski, Maria Rosario, Priyanka Sawant, Nan Ke, Ariel Lefkovith, Anthony D’Ippolito, Matthew Eaton, Susan Henry, Graeme Hodgson
ESMO Congress 2021
Abstract Number: 14P
2021

EARLY EVIDENCE OF DOSE-DEPENDENT PHARMACODYNAMIC ACTIVITY FOLLOWING TREATMENT WITH SY-5609, A HIGHLY SELECTIVE AND POTENT ORAL CDK7 INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS

Kyriakos P. Papadopoulos, Manish R. Sharma, Erika Hamilton, Debra Richardson, Babar Bashir, Dejan Juric, Geoffrey Shapiro, Graeme Hodgson, Nan Ke, Anthony D’Ippolito, Liv Johannessen, Qing Kang-Fortner, Li Zhou, Maria Rosario, William Zamboni, Hina A. Jolin, Catherine Madigan, Michael J. Kelly, David A. Roth
32nd EORTC-NCI-AACR Symposium
Abstract Number: 180
2020

ACTIVITY OF SY-5609, AN ORAL, NONCOVALENT, POTENT, AND SELECTIVE CDK7 INHIBITOR, IN PRECLINICAL MODELS OF COLORECTAL CANCER

Liv Johannessen, Nan Ke, Priyanka Sawant, Wojciech Dworakowski, Tony D’ippolito, Shanhu Hu, Nisha Rajagopal, Matthew Eaton, Graeme Hodgson
American Society of Clinical Oncology (ASCO20) Virtual Scientific Program
Abstract Number: 3585
2020

FIRST-IN-HUMAN PHASE I STUDY OF SY-5609, AN ORAL, POTENT, AND SELECTIVE NONCOVALENT CDK7 INHIBITOR, IN ADULT PATIENTS WITH SELECT ADVANCED SOLID TUMORS

Kyriakos P. Papadopoulos, Manish R. Sharma, Erika Hamilton, Debra Richardson, Babar Bashir, Graeme Hodgson, Li Zhou, Angela Volkert, Hina A. Jolin, Catherine Madigan, Michael Kelly, David A. Roth
American Society of Clinical Oncology (ASCO20) Virtual Scientific Program
Abstract Number: TPS3662
2020

PRECLINICAL EVALUATION OF PK, PD, AND ANTI-TUMOR ACTIVITY OF THE ORAL, NON-COVALENT, POTENT AND HIGHLY SELECTIVE CDK7 INHIBITOR, SY-5609, PROVIDES RATIONALE FOR CLINICAL DEVELOPMENT IN MULTIPLE SOLID TUMOR INDICATIONS

LIV JOHANNESSEN, SHANHU HU, NAN KE, ANTHONY D’IPPOLITO, NISHA RAJAGOPAL, PRIYANKA SAWANT, KRISTIN HAMMAN, JASON MARINEAU, ANNELI SAVINAINEN, WILLIAM ZAMBONI, GRAEME HODGSON
31st EORTC-NCI-AACR MOLECULAR TARGETS AND CANCER SYMPOSIUM
ABSTRACT NUMBER: C091
2019

SY-5609, AN ORALLY AVAILABLE SELECTIVE CDK7 INHIBITOR, DEMONSTRATES BROAD ANTI-TUMOR ACTIVITY IN VIVO

Shanhu Hu, Jason Marineau, Kristin Hamman, Michael Bradley, Anneli Savinainen, Sydney Alnemy, John Carulli, Claudio Chuaqui and Eric Olson
American Association for Cancer Research (AACR) Annual Meeting
Abstract Number: 4421
2019

AN ORAL AND SELECTIVE CDK7 INHIBITOR DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN BREAST AND OVARIAN CANCER MODELS

Shanhu Hu, Jason Marineau, Michael Bradley, Kristin Hamman, Sydney Alnemy, Danielle Smith, John Carulli, Claudio Chuaqui
30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Abstract Number 96
2018